“The patients who were treated with tight control still continue to have the protection, much more than you expect. So the two things that are important are that glycemic control still confers really important treatment effect for the eyes that goes way beyond the clinical trial. The second is the suggestion that fenofibrate may have a real effect on retinopathy and should be considered, especially in those with retinopathy. The take-home is that glycemic control still matters for type II. I always tell my patients you know ‘No drug can do as much as tight glycemic control.’ It’s a mystery but it works.”
Return to Eye Study Underscores the Long-lasting Benefits of Controlling Diabetes Press Release.